Compare Biogen Inc (BIIB) vs Mattel Inc (MAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Mattel Inc — how do they compare? Biogen Inc trades at $196 (market cap $28.34B), while Mattel Inc trades at $13.82 (market cap $3.97B). The key difference: Biogen Inc is far larger — about 7.1× Mattel Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Mattel Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | MAT | |
|---|---|---|
Market Cap | $28.34B | $3.97B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $22.16 |
52-Week Low | $122.68 | $13.05 |
Enterprise Value | $30.62B | $5.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Mattel (MAT) trades at $13.84, up 3.83% today, with a bullish technical signal and strong valuation metrics including a P/E of 8.86 and P/S of 0.81. Recent earnings showed a Q1 2026 beat but Q3-Q4 2025 misses, while revenue stability around $5.4B supports a 9.27% net margin. News highlights include Comic-Con exclusives and a Barbie-Dunkin' collaboration, though cash flow turned negative in 2025.
The stock presents value with low multiples and 50% analyst buy ratings, targeting $14.60 consensus. Risks include volatile earnings, debt load, and activist pressure for a sale. Upside depends on brand execution offsetting consumer spending sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →
